<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834921</url>
  </required_header>
  <id_info>
    <org_study_id>46/15A</org_study_id>
    <nct_id>NCT04834921</nct_id>
  </id_info>
  <brief_title>MCO Membrane Efficiency in Septic Shock Patients</brief_title>
  <official_title>Randomized Blinded Controlled Pilot Study on Clinical Assessment of Continuous Hemodialysis With a High Molecular Flux Membrane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fiorenza Ferrari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Renal Research Institute Vicenza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentre randomized pilot study. All patients received two consecutive RRT: CVVHD&#xD;
      with MCO filter (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration&#xD;
      (CVVHDF) with HFF(AV1000S®) in a controlled randomized (1:1) blinded manner. Crossover&#xD;
      randomized to sequence (A+B or B+A) for 48 h total without washout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a monocentre randomized pilot study. All patients received CVVHD with MCO filter&#xD;
      (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration (CVVHDF) with&#xD;
      HFF(AV1000S®) in a controlled randomized (1:1) blinded manner. Crossover randomized to&#xD;
      sequence (A+B or B+A) for 48 h total without washout.&#xD;
&#xD;
      The efficiency of the filters for small and middle molecules was compared in septic shock&#xD;
      patients with AKI stage 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2017</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">February 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All patients received two consecutive RRT (MCO-CVVHD and HFF-CVVHDF); in a controlled randomized (1:1) blinded manner. Each RRT treatment lasted 24 hours Crossover randomized to sequence (A+B or B+A) for 48 h total without washout</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Blinding procedure was limited to the doctors who collected the data and the external statistician who performed the analysis</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: mean arterial pressure (MAP, mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: heart rate (HR, beat/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: lactate level (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: cardiac index (CI; L/min/m2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: stroke volume variation (SVV; %)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: PVC (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: SVRI (dyn*s/cm5*m2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: SCVO2 (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement in haemodynamic parameters</measure>
    <time_frame>48 hours</time_frame>
    <description>measurements of the hemodynamic parameters: dose of vasopressor or inotropes (mcg/kg/min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clerance of cytokine</measure>
    <time_frame>48 hours</time_frame>
    <description>removal of IL-6 (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clerance of cytokine</measure>
    <time_frame>48 hours</time_frame>
    <description>removal of IL-10 (pg/mL); reduction was evaluated after before and after the RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clerance of cytokine</measure>
    <time_frame>48 hours</time_frame>
    <description>removal of IL-8 (pg/mL); reduction was evaluated after before and after the RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clerance of cytokine</measure>
    <time_frame>48 hours</time_frame>
    <description>removal of MPO (U/L); reduction was evaluated after before and after the RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency for middle molecules</measure>
    <time_frame>48 hours</time_frame>
    <description>measure of the efficacy (Kcd, (ml/kg/h)) of removal of B2microglobulin for each filter according to equation in Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C; Nomenclature Standardization Initiative (NSI) alliance. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care. 2016 Oct 10;20(1):318. Review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency for small molecules</measure>
    <time_frame>48 hours</time_frame>
    <description>measure of the efficacy (Kcd (ml/kg/h)) of BUN for each filter according to equation in Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C; Nomenclature Standardization Initiative (NSI) alliance. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care. 2016 Oct 10;20(1):318. Review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficiency for small molecules</measure>
    <time_frame>48 hours</time_frame>
    <description>measure of Efficacy (Kcd Cr (ml/kg/h)) of removal of SCr for each filter according to equation in Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C; Nomenclature Standardization Initiative (NSI) alliance. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care. 2016 Oct 10;20(1):318. Review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>removal of antibiotics</measure>
    <time_frame>48 hours</time_frame>
    <description>evaluation of plasma level of vancomycin piperacillin/tazobactam(mcg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>removal of antibiotics</measure>
    <time_frame>48 hours</time_frame>
    <description>evaluation of plasma level of vancomycin (mcg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>removal of antibiotics</measure>
    <time_frame>48 hours</time_frame>
    <description>evaluation of plasma level of meropenem(mg/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>MCO-CVVHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVVHD with MCO filter for 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFF-CVVHDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVVHDF with high flux filter for 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultraflux® EMiC®2</intervention_name>
    <description>Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout</description>
    <arm_group_label>HFF-CVVHDF</arm_group_label>
    <arm_group_label>MCO-CVVHD</arm_group_label>
    <other_name>HFF-CVVHDF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years;&#xD;
&#xD;
          -  septic shock according to ACCP/SCCM criteria&#xD;
&#xD;
          -  AKI KDIGO stage 3&#xD;
&#xD;
          -  clinical decision to begin citrate based-RRT for at least 48 hours&#xD;
&#xD;
          -  Hb &gt;= 9 g/dL&#xD;
&#xD;
          -  Obtain the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing chronic renal insufficiency&#xD;
&#xD;
          -  Weight &gt; 125 kg Life expectancy &lt;24 hr&#xD;
&#xD;
          -  Declared do Not Resuscitate or Comfort Measures&#xD;
&#xD;
          -  Platelets &lt; 20 [10^3/ul] or active bleeding&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Contraindication to citrate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fiorenza Ferrari</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27000</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Fiorenza Ferrari</investigator_full_name>
    <investigator_title>Senior Consultant at intensive Care Unit of Hospital San Matteo, Pavoa, Italy</investigator_title>
  </responsible_party>
  <keyword>Renal Replacement Therapy,</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Efficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

